Newsroom

Press Contacts

Amy Speak Principal, Speak Life Science
Media
amy@speaklifescience.com
(617) 420-2461
Jeff Hofmeister, Director, Trade Relations & GPOs
Managed Care
Jeff.Hofmeister@tolmar.com
(224) 880-5770

News Releases

ELIGARD (leuprolide acetate) for Injectable Suspension Continues Growth Momentum With Securing Favorable Formulary Position as the Lowest WAC Priced, and Only Subcutaneously Administered Leuprolide Acetate for the Palliative Treatment of Advanced Prostate Cancer

Formulary placement with Envision RX fuels market-leading growth Chicago, Ill. – June 7, 2019 - Tolmar Pharmaceuticals Inc., a fully integrated specialty pharmaceutical company, today announced new formulary placement for ELIGARD® with Rite-Aid’s Pharmacy Benefits Manager (PBM...

View full release